Truths and lesser truths: An interpretation of clinical trials in glaucoma

Optometry and Vision Science

Volumn 85, Issue 6, 2008, Pages 376-379

  Chauhan, Balwantray C ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Clinical trials; Glaucoma; Risk

Indexed keywords

CLINICAL TRIAL; CLINICAL TRIALS; GLAUCOMA;

CLINICAL STUDY; CORNEA THICKNESS; DISEASE COURSE; GLAUCOMA; HAZARD RATIO; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; LEAF LAMINA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCLERA; VISUAL FIELD; BLINDNESS; CLINICAL TRIAL; CORNEA; LONGITUDINAL STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLINDNESS; CLINICAL TRIALS AS TOPIC; CORNEA; DISEASE PROGRESSION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LONGITUDINAL STUDIES; RISK FACTORS;

EID: 48549104852     PISSN: 10405488     EISSN: None     Source Type: Journal    
DOI: 10.1097/OPX.0b013e318177ec28     Document Type: Review

References (34)

1. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97.
2. The Advanced Glaucoma Intervention Study (AGIS):4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology 1998;105:1146-64.
3. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998;126:498-505.
4. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130: 429-40.
5. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol 2002;134:499-512.
6. Anderson DR, Drance SM, Schulzer M. Natural history of normal-tension glaucoma. Ophthalmology 2001;108:247-53.
7. Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001;131:699-708.
8. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK II, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20.
9. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120: 1268-79.
10. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48-56.
11. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366-75.
12. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53.
13. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK II, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13; discussion 829-30.
14. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72.
15. Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology 2007;114:3-9.
16. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO. Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol 2005;123:1188-97.
17. Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 2000;44:367-408.
18. Ehlers N, Bramsen T, Sperling S. Applanation tonometry and central corneal thickness. Acta Ophthalmol (Copenh) 1975;53:34-43.
19. Whitacre MM, Stein RA, Hassanein K. The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 1993;115:592-6.
20. Kohlhaas M, Boehm AG, Spoerl E, Pursten A, Grein HJ, Pillunat LE. Effect of central corneal thickness, corneal curvature, and axial length on applanation tonometry. Arch Ophthalmol 2006;124:471-6.
21. Herndon LW, Weizer JS, Stinnett SS. Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol 2004; 122:17-21.
22. Kim JW, Chen PP. Central corneal pachymetry and visual field progression in patients with open-angle glaucoma. Ophthalmology 2004;111:2126-32.
23. Stewart WC, Day DG, Jenkins JN, Passmore CL, Stewart JA. Mean intraocular pressure and progression based on corneal thickness in primary open-angle glaucoma. J Ocul Pharmacol Ther 2006;22: 26-33.
24. Chauhan BC, Hutchison DM, LeBlanc RP, Artes PH, Nicolela MT. Central corneal thickness and progression of the visual field and optic disc in glaucoma. Br J Ophthalmol 2005;89:1008-12.
25. Congdon NG, Broman AT, Bandeen-Roche K, Grover D, Quigley HA. Central corneal thickness and corneal hysteresis associated with glaucoma damage. Am J Ophthalmol 2006;141:868-75.
26. Jonas JB, Stroux A, Velten I, Juenemann A, Martus P, Budde WM. Central corneal thickness correlated with glaucoma damage and rate of progression. Invest Ophthalmol Vis Sci 2005;46:1269-74.
27. Schulzer M, Mikelberg FS, Drance SM. Some observations on the relation between intraocular pressure reduction and the progression of glaucomatous visual loss. Br J Ophthalmol 1987;71:486-8.
28. O'Brien C, Schwartz B, Takamoto T, Wu DC. Intraocular pressure and the rate of visual field loss in chronic open-angle glaucoma. Am J Ophthalmol 1991;111:491-500.
29. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991;111:51-5.
30. Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, Caprioli J. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627-35.
31. Martinez-Bello C, Chauhan BC, Nicolela MT, McCormick TA, LeBlanc RP. Intraocular pressure and progression of glaucomatous visual field loss. Am J Ophthalmol 2000;129:302-8.
32. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology 2007;114:205-9.
33. Heijl A, Lindgren A, Lindgren G. Test-retest variability in glaucomatous visual fields. Am J Ophthalmol 1989;108:130-5.
34. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Epidemiology, 2nd ed. Boston: Little, Brown; 1991.